PRESS RELEASES

December 2, 2020

4D Molecular Therapeutics Strengthens Leadership Team with Key Appointments in Clinical Research and Development

Emeryville, CA – December 2, 2020 – 4D Molecular Therapeutics (4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that Robert Fishman, M.D. has joined as Chief Medical Officer & Therapeutic ...

November 18, 2020

4D Molecular Therapeutics Appoints Nancy Miller-Rich and Shawn Tomasello to its Board of Directors

Emeryville, CA – November 18, 2020 – 4D Molecular Therapeutics (4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced the appointment of Nancy Miller-Rich and Shawn Tomasello to the Board of Directors. ...

September 8, 2020

4D Molecular Therapeutics Appoints John F. Milligan, Ph.D., as Executive Chairman of Board of Directors

Emeryville, CA – September 8, 2020 – 4D Molecular Therapeutics (4DMT), a clinical-stage leader in the development of precision-guided AAV gene therapy based on directed evolution, announced the appointment of John F. Milligan, Ph.D. as Executive Chairman of the ...

August 26, 2020

4D Molecular Therapeutics Appoints Susannah Gray to Board of Directors

Emeryville, CA – August 27, 2020 – 4D Molecular Therapeutics (4DMT), a clinical-stage leader in the development of precision-guided AAV gene medicines based on directed evolution, announced the appointment of Susannah Gray to the Board of Directors. Ms. Gray brings ...